• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Document Archive

Document Archive Breakpoint tables for fungi QC tables Methodology Rationale documents Clinical breakpoints for fungi (v 11.0) - pdf file for printing (until 26 June, 2025) Clinical breakpoints for fungi (v 11.0) - excel file for screen (until 26 June, 2025) Clinical breakpoints for fungi (v 10.0) -…

Get to know more

Mycobacteria (AMST)

Mycobacteria (AMST) The EUCAST AMST develops breakpoints and methods for antimicrobial susceptibility testing of mycobacteria. Clinical breakpoints for Mycobacteria are part of the regular EUCAST breakpoint table for bacteria. For MIC distributions for Mycobacterium tuberculosis and other…

Get to know more

Fungi (AFST)

Fungi (AFST) The EUCAST AFST develops breakpoints and methods for antimicrobial susceptibility testing of fungi. Clinical breakpoints for fungi are listed in a separate document and are not included into the breakpoint table for bacteria. For MIC distributions for fungi, go to the EUCAST MIC…

Get to know more

Breakpoints in Brackets

Breakpoints in brackets in EUCAST tables EUCAST breakpoints in brackets Guidance document, 1 December, 2021 Download PDF Recently, EUCAST introduced the concept of “breakpoints in brackets” to warn against the use of specific agents without the use of additional therapeutic measures. For these…

Get to know more

Development of clinical breakpoints and ECOFFs

Development of clinical breakpoints and ECOFFs As with other breakpoints for antimicrobials the background for EUCAST breakpoints are given in Rationale Documents. Since for antifungals specific technical issues in testing may exist, technical notes are developed if needed. As with the general…

Get to know more

Rationale Documents

Rationale Documents Rationale documents pertaining to breakpoints determined by the EUCAST Veterinary Subcommittee. Florfenicol (Cattle) Rationale for EUCAST clinical breakpoints, version 1.0 10 August 2019 Download PDF Amoxicillin-Clavulanic Acid (AMC) Dog: oral and iv administration (VetCAST)…

Get to know more

Guidance Documents

Guidance Documents All Antibiotic Infection Methodology Pathogen Regulatory Document Title Date of Publication Previous Versions and Notes Infective endocarditis - EUCAST guidance on the reporting of antimicrobial susceptibility testing results July 2025 December 2024 Daptomycin in endocarditis and…

Get to know more

Public consultations

Public consultation Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Previous public consultations with comments and EUCAST responses 2025 Archive Proposed new breakpoints for…

Get to know more

When there are no antifungal breakpoints

When there are no antifungal breakpoints? 16 April 2024 first published on 16 April 2024, errata published 30 Sep, 2024: “dashes (“-“) are replaced by R, C. dubliniensis has been deleted as BPs have been set, and the species (dermatis) specified in table 2.” Download PDF EUCAST guidance on…

Get to know more

Development of Clinical Breakpoints and ECOFFs

Development of Clinical Breakpoints and ECOFFs The EUCAST AMST develops breakpoints and methods for antimicrobial susceptibility testing of mycobacteria. Rationale Documents Discover More Public Consultations A chance to review proposed EUCAST changes. Discover More Submit non-truncated MIC…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here